INTRODUCTION {#s1}
============

Breast cancer is the most frequent cancer in female. In recent years, with the trend of younger age and increasing morbidity, it threatens the health of women seriously, but the mechanism isn\'t clear \[[@R1], [@R2]\]. Breast cancer has obvious heterogeneity on molecular phenotype, tissue pathology and clinical characteristics. Nowadays, the focus of treatment strategy is using chemotherapy to induce tumor cell apoptosis, resistance to hormone receptor and targeted therapy. Meanwhile, growing evidence has demonstrated the important role of tumor microenvironment in the development of cancer and the treatment aim at interfering the microenvironment and metabolism stimulation has gained clinical utility \[[@R3]--[@R5]\]

Macrophage is a main kind of immune cell infiltrating to tumor microenvironment and it can change its phenotype according to the signal stimulation of microenvironment. TAMs are generally characterized by the expression of cell surface marker CD68 \[[@R6]\]. Macrophages can be divided into classically activated M1 and selectively activated M2 \[[@R7], [@R8]\]. M1 macrophages are induced by TLR (toll like receptor) and IFN-γ, expressing high level of CD86, CD40 and PD-L1 and play the role of pro-inflammatory and anti-tumor response \[[@R9]\]. While M2 is totally different, they are characterized by the expression of CD163, CD206, CD204 and arginase-1, secreting IL-10 and TGF-β, expressing VEGF (vascular endothelial growth factor) and promoting both the activation of tumor related regulatory T cells and matrix formation, all of which promote tumor progression \[[@R10]--[@R12]\].

Plentiful studies have confirmed that TAMs are associated with poor outcome of human cancer, such as hepatoma, gastric cancer, lung cancer and so on \[[@R13]--[@R16]\]. However, other studies have opposite reports \[[@R17]\]. Studies reveal that macrophage subtype, location, density are all in correlation with cancer survival \[[@R18], [@R19]\]. For breast cancer, studies have shown that density of TAMs is related to hormone receptor status, stage, lymph node metastasis and poor prognosis \[[@R2], [@R18]--[@R21]\]. However, further studies are needed to clarify the influence of TAMs including the role of intratumoral distribution and surface marker selection. Therefore, we conducted a detailed meta-analysis summarizing the related evidence to evaluate the prognostic value of TAMs in human breast cancer.

RESULTS {#s2}
=======

Search results and study characteristics {#s2_1}
----------------------------------------

Literature retrieval yield 3148 records and we selected 58 candidate studies (Figure [1](#F1){ref-type="fig"}). By further screening, 42 articles are excluded because of lacking survival data and canine tissue samples. Finally, 16 citations with valid survival data were included.

![Selection of studies\
Flow chart showed the selection process of the included studies](oncotarget-08-30576-g001){#F1}

The characteristics of included study containing OS, DFS, RFS, BCSS data were listed in Table [1](#T1){ref-type="table"}. There are 4541 patients in total of included studies. And the sample size for OS, DFS, RFS, BCSS was 1699, 916, 1593, 1634 separately. All the studies used IHC staining in formalin-fixed paraffin-embedded tissue blocks to evaluate TAMs biomarker expression. When evaluating TAM density, 50% studies performed blinded and independent reading. Cut-off value for definition of TAMs density low versus high could be retrieved from 15 articles (Table [1](#T1){ref-type="table"}).

###### Characteristics of the eligible studies

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Ref                     Patient No.   Age median (range)   Follow-up median (range)   Cutoff value                                                                                                  Macrophage density       Tissue distribution                         Analysis                  Marker             Company                                                    Stage   NOS Score   Result
  ----------------------- ------------- -------------------- -------------------------- ------------------------------------------------------------------------------------------------------------- ------------------------ ------------------------------------------- ------------------------- ------------------ ---------------------------------------------------------- ------- ----------- -------------
  Koru-Sengul,T. (2016)   150           54.9±12.4            116 (2-326)                1+=1--150 cells/mm^2^ 2+=151--300 cells/mm^2^ 3+=\> 300 cells/mm^2^ CD163/CD206 2+/3+ vs 1+ CD40 1+/2+ vs 0   cells/mm^2^              tumor nest and stroma                       blind and independent     CD163 CD206 CD40   CD163/206/40 R&D,Minneapolis                               I-IV    8           OS

  Yang, J. (2015)         100           55 (28-80)           60                         \>61.14±23.76 \<61.14±23.76                                                                                   high-power field(HFP)    tumor nest and stroma /peritumoral stroma   no                        CD68               DAKO, Carpinteria, CA                                      I-IV    6           OS

  Sousa, S. (2015)        562           52.5 (26-65)         35 (25.5--43.6)            \>369;≤369                                                                                                    cells/mm^2^              tumor mest and stroma                       double- blinded fashion   CD68 CD163         CD68(Abcam,CambridgeUK);CD163(Novocastra, New-castle,UK)   I-IV    8           RFS

  Gwak,J.M. (2015)        372           50.96 (26-87)        92.4 (1.2-127.2)           intratumoral:\>24.2;≤24.2 stromal:\>35.3;≤35.3                                                                high-power field(HPF)    tumor nest vs stroma                        no                        CD68               Dako, Carpinteria, CA                                      I-III   7           DFS

  Satu Tiainen (2015)     278           59 (32-86)           75.6 (4.8-133.2)           CD163:\>26;≤26 CD68:\>34;≤34                                                                                  high-power field(HPF)    tumor nest and stroma                       blind and independent     CD163 CD68         Thermo Scientific                                          I-III   8           OS

  Yuan,Z.Y. (2014)        287           NA                   89 (4--181)                \>16;≤16                                                                                                      high-power field(HPF)    stroma                                      no                        CD68               Thermo Fisher Scientific, Waltham, MA, USA                 I-III   7           OS/DFS

  Zhang,Y. (2013)         172           49 (29-73)           60                         ≥26 /tissue cores \<26 /tissue cores                                                                          high-power field(HPF)    stroma                                      blind                     CD68               Abcam, USA                                                 I-IV    7           OS/DFS

  Carrio,R. (2013)        29            59 (32-87)           138 (24-292)               ≥5 TAMs/slide; \<5 TAMs/slide                                                                                 high-power field(HPF)    tumor nest                                  blind                     CD68               Carpinteria, CA, USA                                       I       7           OS

  Campbell,M.J (2013)     102           NA                   100                        \>24;≤24                                                                                                      high-power field(HPF)    tumor nest and stroma                       no                        CD68+ /PCNA+       Dako, Cambridgeshire, UK                                   I-III   7           RFS

  Mohammed,Z.M. (2012)    468           NA                   165                        ≥3%; \<3%                                                                                                     high-power field(HPF)    tumor nest and stroma                       blind and independent     CD68               Dako, Glostrup, Denmark                                    I-III   8           RFS

  Medrek, C. (2012)       144           65 (34-97)           78.6 (3.96-90.6)           absent/sparse (0-2)\                                                                                          high-power field (HPF)   tumor nest vs stroma                        no                        CD68 CD163         CD163 Novocastra CD68 DAKO                                 I-III   8           OS/RFS/BCSS
                                                                                        dense (3)                                                                                                                                                                                                                                                                                                      

  Mahmoud,S.M. (2012)     1322          \<70                 127 (1-192)                intratumoral:\>6;≤6 stromal:\>17;≤17                                                                          high-power field(HPF)    tumor nest and stroma                       blind                     CD68               Dako, Glostrup,Denmark                                     I-III   6           BCSS

  Campbell,M.J (2011)     216           55.75                108                        \>5;≤5                                                                                                        high-power field(HPF)    tumor nest and stroma                       no                        CD68+ /PCNA+       Dako, Cambridgeshire, UK                                   I-III   8           OS/RFS

  Mukhtar,R.A. (2011)     70            50 (30-74)           87.6 (6--156)              \>38.5;≤38.5                                                                                                  high-power field(HPF)    tumor nest and stroma                       blind and independent     CD68+ /PCNA+       Dako, Cambridgeshire, UK                                   I-III   8           OS

  Murri,A.M. (2008)       168           \>50 (81%)           72                         NA                                                                                                            NA                       tumor and surrounding stroma                blind and independent     CD68               Dako, Cambridgeshire, UK                                   I-III   7           BCSS\
                                                                                                                                                                                                                                                                                                                                                                                                       /OS

  Leek,R.D. (1996)        101           NA                   60                         \>12;≤12                                                                                                      high-power field(HPF)    tumor nest and stroma                       no                        CD68               Dako, Cambridgeshire, UK                                   NA      6           RFS
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: NA: Not available; OS: overall survival; DFS: disease-free survival; RFS: relapse-free survival; BCSS: breast cancer specific survival; NOS: Newcastle-Ottawa Scale checklist.

TAMs definition and density {#s2_2}
---------------------------

The introduction of the antibodies and definition method of TAMs of included studies were shown in Table [1](#T1){ref-type="table"}. 15 studies used CD68, 4 studies used CD163 and only one study used CD206 and CD40. Of all the studies using CD68, 18.75% using CD68+/PCNA+.

Data synthesis: clinicopathological features {#s2_3}
--------------------------------------------

Our results showed that high TAMs infiltration were significantly correlated to age (OR = 1.211 (1.031, 1.422), fixed-effect model), size (OR = 0.73 (0.616, 0.865), fixed-effect model), histologic grade (OR = 0.344 (0.257, 0.459), random-effect model), ER status (OR = 2.760 (1.808, 4.213), random-effect model), PR status (OR = 2.188 (1.825, 2.623), fixed-effect model), basal phenotype (OR = 0.436 (0.346, 0.550), fixed-effect model), vascular invasion (OR = 0.623 (0.509, 0.763), fixed-effect model). On the contrary, high TAMs infiltration was not found to be associated with lymph node status (OR = 0.843 (0.646, 1.099), random-effect model), HER-2 status (OR = 0.807 (0.459, 1.418), random-effect model). These results indicated that breast cancer with high TAMs infiltration exhibited aggressive biological behaviors (Table [2](#T2){ref-type="table"}).

###### Meta-analysis for the association of increased total TAMs expression and clinicopathological features of breast cancer patients

  Clinicopathological features             No.of studies   No.of patients   Model    OR(95% CI)           P-Value   Heterogeneity          
  ---------------------------------------- --------------- ---------------- -------- -------------------- --------- --------------- ------ -------
  Age(≤50 vs. \>50)                        6               2708             Fixed    1.211(1.031,1.422)   0.02      3.45            0      0.63
  Size(≤2cm vs. \>2cm)                     6               2698             Fixed    0.73(0.616,0.865)    0         7.41            32.5   0.192
  Histologic grade(G1-2 vs. G3)            9               3141             Random   0.344(0.257,0.459)   0         20.96           61.8   0.007
  lymph node status(N0 vs. N1-3)           6               2904             Random   0.843(0.646,1.099)   0.206     13.71           48.9   0.057
  ER status(Negative vs. Positive)         7               2788             Random   2.760(1.808,4.213)   0         31.74           77.9   0
  PR status(Negative vs. Positive)         5               2159             Fixed    2.188(1.825,2.623)   0         4.59            0      0.468
  HER-2(Negative vs. Positive)             7               2558             Random   0.807(0.459,1.418)   0.456     45.37           84.6   0
  Basal phenotype(Negative vs. Positive)   6               2268             Fixed    0.436(0.346,0.550)   0         0.97            0      0.915
  Vascular invasion(Absent vs. Present)    3               1869             Fixed    0.623(0.509,0.763)   0         3.14            36.4   0.208

Data synthesis: overall survival {#s2_4}
--------------------------------

High density of TAMs was associated with poor OS, HR = 1.504 (1.200, 1.884), I^2^ = 40.2% (Figure [2A](#F2){ref-type="fig"}). Besides, the results of subgroup analysis according to location were 1.42 (1.17, 1.72), 0.27 (0.04, 1.85), 1.98 (0.97, 4.04) of TN+TS (tumor nest and stroma), TN (tumor nest) and TS (tumor stroma) group separately (Figure [2B](#F2){ref-type="fig"}). According to biomarker, HR = 1.83 (1.41, 2.38)/1.13 (0.62, 2.07)/1.44 (0.99, 2.09)/0.97 (0.61, 1.54) of CD68, CD163, CD206, CD40 separately(Figure [2C](#F2){ref-type="fig"}).

![The forest plots of HRs for OS\
Forest plots and meta-analysis of studies evaluating HRs of high TAM counts as compared to low counts. Survival data were reported as OS **A**., as well as subgroup analysis of location **B**. and biomarker **C**. among included studies. TN: tumor nest; TS: tumor stroma.](oncotarget-08-30576-g002){#F2}

Data synthesis: disease free survival {#s2_5}
-------------------------------------

High density of TAMs was related to poor DFS, HR = 2.228(1.716, 2.892), I^2^ = 0% (Figure [3A](#F3){ref-type="fig"}). And results were associated with TN (tumor nest) and TS (tumor stroma) with HR = 3.14 (1.46, 6.75)/2.08 (1.57, 2.78) separately, I^2^ = 0% (Figure [3B](#F3){ref-type="fig"}). And we also conducted a subgroup meta-analysis according to hormone status and results in all subgroups showed obvious significance (Figure [3C](#F3){ref-type="fig"}).

![The forest plots of HRs for DFS\
Forest plots and meta-analysis of studies evaluating HRs of high TAM counts as compared to low counts. Survival data were reported as DFS **A**., as well as subgroup analysis of the location **B**. and hormone status **C**. of included studies. TN: tumor nest; TS: tumor stroma.](oncotarget-08-30576-g003){#F3}

Data synthesis: relapse free survival {#s2_6}
-------------------------------------

We didn\'t find relationship between TAMs density and RFS, with HR = 1.799 (0.972, 3.330), I^2^ = 82.5% (Figure [4A](#F4){ref-type="fig"}). Then subgroup analysis was conducted to find the origin of heterogeneity. According to location of TAMs, we divided our studies into three groups: TS, TN+TS, TN. However, because of different biomarker, hormone status within these studies, it\'s hard to eliminate heterogeneity (Figure [4B](#F4){ref-type="fig"}).

![The forest plots of HRs for RFS\
Forest plots and meta-analysis of studies evaluating HRs of high TAM counts as compared to low counts. Survival data were reported as RFS **A**., as well as subgroup analysis of the location **B**. Abbreviations: TN: tumor nest; TS: tumor stroma.](oncotarget-08-30576-g004){#F4}

Data synthesis: breast cancer special survival {#s2_7}
----------------------------------------------

Results of high density of TAMs *versus* low showed no difference for BCSS, HR = 0.786 (0.505, 1.222), I^2^ = 68.6% (Figure [5A](#F5){ref-type="fig"}). Then we conducted subgroup analysis according to location and there was still no difference(Figure [5B](#F5){ref-type="fig"}).

![The forest plots of HRs for BCSS\
Forest plots and meta-analysis of studies evaluating HRs of high TAM counts as compared to low counts. Survival data were reported as BCSS **A**., as well as subgroup analysis of the location **B**. Abbreviations: TN: tumor nest; TS: tumor stroma.](oncotarget-08-30576-g005){#F5}

Publication bias {#s2_8}
----------------

We use funnel plot analysis and Egger\'/Begg\' test to evaluate publication bias and there was no statistical difference for OS, DFS, RFS and BCSS with P value of 0.574/ 0.787, 0.019 /0.293, 0.368/ 0.805, 0.314/ 0.322 separately. Begg\'s funnel plots with pseudo 95% confidence limits of the four groups were listed in Figure [6A-6D](#F6){ref-type="fig"}.

![Funnel graph for assessment of potential publication bias in studies of TAM density in patients with breast cancer\
Publication bias of OS **A**., DFS **B**., RFS **C**., BCSS **D**. of the meta-analysis showed no statistical significance (*p* \> 0.05) using Begg\'s test.](oncotarget-08-30576-g006){#F6}

Sensitivity analysis {#s2_9}
--------------------

Results of removal of each study at a time could be seen in Figure [7A-7D](#F7){ref-type="fig"}. For the OS and DFS analysis, removal of each study didn\'t change HR significantly. For the RFS analysis, removal of "Mohammed,Z.M(ER-) 2012" had an important effect of the results. For BCSS, removal of "Mahmoud, SM 2012" also affect the overall results.

![Sensitivity for included studies\
The effect of single study was evaluated on the whole results of OS **A**., DFS **B**., RFS **C**., BCSS **D**. in this meta-analysis.](oncotarget-08-30576-g007){#F7}

DISCUSSION {#s3}
==========

Mountains of studies have illustrated the role of TAMs in cancer initiation and progression \[[@R2], [@R4], [@R22]--[@R24]\]. But the pertinence between TAMs and outcomes of breast cancer hasn\'t been illuminated. In our meta-analysis, we chose OS, DFS, RFS and BCSS to assess risk of high macrophage density. Moreover, we analyzed the correlation between clinicopathological features and TAMs infiltration and found high TAMs infiltration was related to both poor survival rates and malignant biological behavior.

Our meta-analysis of 16 studies with 4541 patients in total shown that high density of TAMs was related to worse OS and DFS. What\'s more, we found that the prognostic significance of TAMs was affected by different biomarker, TAMs location and ER receptor status. High density of TAMs was related to poor prognosis and subgroup analysis showed that CD68 was better than M2 specific marker CD163 and CD206 alone in predicting OS. And results of subgroup analysis of location shown both TN+TS and TS group signified worse OS, while there was no difference of TAMs in TN group. All the results indicated that CD68 and TAMs in tumor stroma were strongly associated with worse OS. For DFS, high density of TAMs had the similar prognostic significance as OS outcome.

Results of elevated TAMs of RFS shown no obvious correlation. And the sensitivity analysis shown the exclusion of study of "Mohammed,Z.M(ER-) 2012" obviously affect the association between TAMs density and RFS. This article mentioned above reported an improved recurrence-free survival of CD68 TAMs in ER- breast cancer, which was opposite to some other studies \[[@R25]--[@R27]\]. With regard to BCSS, results showed no statistical significance, HR = 0.95(0.79,1.13). So far, the reasons for such discrepancies using similar methodology are unclear, however, some evidence declares macrophage markers, such as CD68 may be expressed by other non-myeloid tissues in cancer \[[@R28]\]. Besides, the heterogeneity of RFS and BCSS is considerable, maybe the results should be considered cautiously.

Furthermore, we analyzed association between TAMs infiltration and several clinicopathological parameters. Results indicated high density of TAMs was related to younger age, larger size, high histologic grade, negative hormone receptor status, malignant phenotype and vascular invasion, which were all crucial factors for predicting the prognosis. Thus, high density of TAMs may lead to poor survival rates by promoting tumor proliferation, migration and invasion.

This study has some important implications in breast cancer. Firstly, it demonstrates high TAMs are related to worse outcome, which indicates that TAMs may be a potential therapeutic target. Secondly, it shows the tissue distribution and CD68 biomarker of TAMs has an important role in prognostic prediction.

There are also limitations in this meta-analysis. First of all, the markers and cut-off values for assessing TAMs expression of individual studies are inconsistent and cut-off value may be a source of considerable interstudy heterogeneity. Besides, although Begg\'s and Egger\'s test were performed and there was no statistical significance. Results should be interpreted cautiously because we only include studies with available HR value or K-M survival curves with necessary data.

In short, our analyses show that high density of TAMs in breast cancer tissues, especially CD68+ TAMs in tumor stroma, is associated with worse prognosis in human breast cancer. As main kind infiltrating cells in tumor microenvironment, TAMs have a close relationship with tumor cells by direct or indirect function \[[@R29]\]. Some factors secreted by TAMs also been reported to be correlated with poor prognosis \[[@R30], [@R31]\]. Targeted therapies directly targeting TAMs, or reprogramming TAMs to M1phenotype could be promising in improving survival rates of breast cancer patients.

MATERIALS AND METHODS {#s4}
=====================

Search strategy {#s4_1}
---------------

This meta-analysis was conducted according to PRISMA guidelines. We searched PubMed (MEDLINE), Web of science and Embase from their inception until July 1, 2016 and the records and results are shown in Figure [1](#F1){ref-type="fig"}. The following Mesh Terms or key words were used in the search: "cancer", "tumor", "neoplasm", "carcinoma", "macrophages" and "breast cancer". The language was restricted to English. The references from identified articles were manually searched for additional relevant records.

Inclusion criteria {#s4_2}
------------------

Inclusion criteria for primary studies were as follows:(1) proven diagnosis of breast cancer by pathology ; (2) without previous cancer history; (3) evaluating TAMs by CD68, CD206, CD163 using immunochemistry; (4) reporting the correlation of TAMs with OS, DFS, RFS, BCSS and clinicopathological features; (5) full-text studies published in English. Only articles conforming to all the five conditions above were selected, or they would be excluded. Two authors (ZXX and QJK) independently extracted all data. If there were disagreements, we solved by reaching a consensus or discussion with a third investigator. The names of authors and the medical centers involved were examined in each publication to avoid repeated data. The quality of included studies was assessed by using the Newcastle-Ottawa Scale checklist (NOS).

Statistical analyses {#s4_3}
--------------------

Included studies were divided into four groups for analysis: OS, DFS, RFS and BCSS. To integrate survival results, data of TAMs density of survival in individual study was extracted by estimating HRs and 95% confidence interval values. Firstly, we searched original article to get HRs and 95% CI. If data were only available in the form of figures, we read Kaplan-Meier curves by Engauge Digitizer version 4.1 (free software downloaded from <http://sourceforge.net>) and extracted survival data HRs and 95%CI \[[@R32]\]. Moreover, data of clinicopathological features was extracted in study available by estimating ORs. The heterogeneity of included studies across the results was assessed by using I2 statistics and P value, and if I^2^ \> 50% or *P* \< 0.1, the results was considered statistically significant and random-effects models are employed. If *P*≥0.1 and I^2^ ≤ 50%, fixed-effects models are employed. If the 95% CI didn\'t overlap 1, or *P* \< 0.05, results would be considered statistically significant. Statistical analyses were performed using Stata 13.0 (Stata Corporation, College Station, TX).

Sensitivity analyses {#s4_4}
--------------------

We carried out sensitivity analysis, also named influence analysis, to evaluate the effect of single study on the whole results and meanwhile try to find the origin of heterogeneity for each survival outcome group.

Publication bias {#s4_5}
----------------

Publication bias was assessed graphically using funnel plots, and funnel plot Symmetry was evaluated by Begg\'s and Egger\'s linear regression method (*p* \< 0.05 was considered statistically significant publication bias).
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